Forxiga trial shows clinically meaningful improvements in glycemic control among patients aged 10–17 years
Positive results from the T2NOW Phase III trial demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga (dapagliflozin) compared with patients receiving placebo. Adjusted ...
Oct 11, 2023
0
20